ADMINISTRATION INFORMATION

Title

Effects of individual components of remote monitoring for implantable

cardioverter defibrillators or cardiac resynchronisation therapy defibrillators:

protocol for a systematic review and component network meta-analysis

Registration

In accordance with the guidelines, our systematic review protocol was registered with

the International Prospective Register of Systematic Reviews (PROSPERO) on 7 March

2024 (registration number CRD42024517406).

Authors

Makiko Okazaki[1,2], Natsuko Sekiguchi[3], Yuki Sahashi[4,5], Hisashi Noma[6], Takahiro

Mihara[1]

[1] Department of Health Data Science, Yokohama City University Graduate School of

Data Science, Yokohama, Japan

[2] Department of Clinical Engineering, Sakakibara Heart Institute, Fuchu, Japan

[3] Division of Nursing, Higashigaoka Faculty of Nursing, Tokyo Healthcare University,

Meguro, Japan

[4] Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, USA

[5] Department of Cardiology, Gifu University, Gifu, Japan

[6] Department of Data Science, The Institute of Statistical Mathematics, Tachikawa,

Japan

Corresponding author: Takahiro Mihara

Department of Health Data Science, Yokohama City University Graduate School of

Data Science, Yokohama 236-0027, Japan

Phone number: +81-45-787-2800

E-mail: meta.analysis.r@gmail.com

Funding

This research did not receive any specific grants from funding agencies in the public,

commercial, or not-for-profit sectors.

Conflict of interest statement

None declared.

ABSTRACT

Introduction: Currently, the standard of care for patients with cardiac implantable

electronic devices (CIEDs) such as implantable cardioverter-defibrillators (ICD) and

cardiac resynchronisation therapy-defibrillators (CRT-D) involves a combination of

in-person outpatient visits and remote monitoring (RM). RM consists of scheduled

remote device interrogation and automated transmission of prespecified alerts (alert

transmission) at varying frequencies depending on manufacturers and institutions.

However, the effects of RM factors on prognosis remain unclear. This systematic review

and component network meta-analysis (CNMA) will aim to investigate which RM

components (device interrogation, alert transmission, and data transmission frequency)

have the greatest impact on prognosis in patients with ICD or CRT-D.

Methods and analysis: A systematic review will be conducted using MEDLINE

(PubMed), Embase, the Cochrane Central Register of Controlled Trials, the Web of

Science, Clinical Trials.gov, the WHO International Clinical Trials Registry Platform

(ICTRP), the European Union Clinical Trials Register (EU-CTR), and the University

Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR). We will

include randomised controlled trials (RCTs) assessing the effect of RM on patient

outcomes in individuals with ICD or CRT-D. The primary outcome will be

hospitalisation due to cardiovascular disease, heart failure, and device-related

complications. Three reviewers will independently screen the titles and abstracts of

identified studies. Two reviewers will extract data independently, and risk of bias will be

assessed by one reviewer and verified by a second. Random-effects model pairwise

meta-analysis, random-effects network meta-analysis (NMA), and additive CNMA will

be applied in data synthesis. To assess the quality of evidence, we will employ the

Grading of Recommendations Assessment, Development, and Evaluation (GRADE)

approach for pairwise meta-analysis and the Confidence in Network Meta-Analysis

(CINeMA) approach for NMA.

Ethics and dissemination: Ethics approval is not required as this study will use

existing published data. The results will be submitted for publication in a peer-reviewed

journal.

PROSPERO registration number: CRD42024517406.

Keywords: Remote Monitoring; Defibrillators, Implantable; Cardiac Resynchronisation

Therapy Devices; Network Meta-Analysis; Outpatients; Hospitalization; Randomized

Controlled Trials

INTRODUCTION

Rationale

Implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation

therapy-defibrillator (CRT-D) implantation improves cardiac function and prevents

sudden arrhythmic death [1, 2]. The current post-implantation standard of care involves

a combination of in-person outpatient visits and remote monitoring (RM) [3, 4]. To date,

several studies have examined the safety and efficacy of RM [4-6] and reported that RM

reduces the number of in-person outpatient visits without compromising safety [5],

decreases all-cause mortality [6], and reduces emergency clinic visits in patients with

heart failure and ICD or CRT-D implants [7]. These studies have predominantly

compared RM with conventional in-person outpatient care.

RM involves scheduled remote device interrogation and automated transmission of

prespecified alerts (alert transmission) [8]. Furthermore, the frequency of remote data

transmission varies depending on the manufacturers and institutions involved in

reported studies [9]. The frequency of in-person outpatient visits also differs between

patients with and without RM, with RM often allowing for extended intervals [5, 7, 8].

In addition, the combination of in-person outpatient visits, scheduled remote device

interrogation, and alert transmission demands substantial staff time [10]. Therefore,

identifying which RM components (i.e., scheduled interrogation and alert transmission,

including interrogation intervals) have the greatest impact on patient outcomes is crucial

to understanding which component should be prioritised in patient management.

However, the effects of RM components on outcomes and patient management remain

unclear.

Component network meta-analysis (CNMA) allows the estimation of the individual

effects of multiple components within complex interventions [11]. Therefore, the study

will utilise CNMA to elucidate the relative effects of remote device interrogation, alert

transmission, and data transmission frequency on patient outcomes.

Objectives

The objective of this systematic review will be to evaluate which components of RM

have the greatest impact on prognosis in patients with ICD or CRT-D.

METHODS

Study design

The study will be a systematic review incorporating CNMA. This protocol follows the

Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols

(PRISMA-P) guidelines [12]. The systematic review will be reported using the PRISMA

guidelines extension for systematic reviews incorporating network meta-analyses of

health care interventions (PRISMA-NMA) [13] to structure the contents of the final

report. We will conduct CNMA according to PRISMA-NMA guidelines and the

Cochrane Handbook for Systematic Reviews of Interventions version 6.4 [13, 14]. This

protocol has been registered with the International Prospective Register of Systematic

Reviews (PROSPERO) (registration number: CRD42024517406).

Eligibility criteria

We will include randomised controlled trials (RCTs), including re-analyses of

previously published RCTs that did not originally include the outcomes covered by this

study. We will exclude quasi-experimental studies.

Participants

We will include studies examining patients who underwent ICD or CRT-D implantation

and studies involving other cardiac implantable electronic devices (CIEDs) if ICD or

CRT-D data are reported separately.

Interventions

RM involving data transmission without in-person interaction will be included. RM will

comprise scheduled interrogation and alert transmission. In clinical practice, the

schedule of remote interrogations is typically determined by treating physicians in

accordance with clinical guidelines [3,4]. Thus, in CNMA, intervention components

will be classified as short-interval remote interrogation (<1 month), long-interval remote

interrogation (≥1 month), or alert transmission.

Comparators

Conventional in-person outpatient visits will be the reference component, as these are

the most common comparators reported in published studies and are routinely

performed in clinical practice. The frequency of in-person outpatient visits differs

between patients with and without RM, with RM often allowing longer intervals.

Therefore, in CNMA, in-person outpatient visits will be classified as short-interval

in-person outpatient visits (<12 months) and long-interval in-person outpatient visits

(≥12 months).

Outcomes

Studies including at least one of the following outcomes are eligible including outcomes

reported as a component of a composite outcome:

·   hospitalisation (cardiovascular, heart failure, device-related)

·   mortality (all-cause, cardiovascular)

·   unscheduled outpatient visits

·   unscheduled hospitalisation

Timing

No restrictions on follow-up periods will be applied.

Setting

No restrictions on setting will be applied.

Language

We will not impose language restrictions in our literature searches.

Information sources

We will use MEDLINE (PubMed), Embase, the Cochrane Central Register of

Controlled Trials, and the Web of Science. The reference lists of the relevant articles

will also be searched. Further, we will conduct searches via Clinical Trials.gov, the

WHO International Clinical Trials Registry Platform (ICTRP), the European Union

Clinical Trials Register (EU-CTR), and the University Hospital Medical Information

Network Clinical Trials Registry (UMIN-CTR).

Search strategy

Search strategies will be developed using medical subject headings (MeSH) and free

text words relating to ICD, CRT-D, and RM. The proposed search strategy for

MEDLINE is presented in Table 1. Search strategies for other databases, registries, and

websites are explained in Supplementary File 1.

Table 1 Search strategy for PubMed

Number	Search terms
#1	"defibrillators, implantable"[MeSH Terms] OR ("implantable"[Title/Abstract] AND "cardioverter*"[Title/Abstract]) OR ("implantable"[Title/Abstract] AND "defibrillator*"[Title/Abstract]) OR ("implantable"[Title/Abstract] AND "cardioverter"[Title/Abstract] AND "defibrillator*"[Title/Abstract]) OR "cardiac resynchronization therapy devices"[MeSH Terms] OR ("cardiac"[Title/Abstract] AND "resynchronization"[Title/Abstract]) OR ("cardiac"[Title/Abstract] AND "resynchronisation"[Title/Abstract]) OR ("resynchronization"[Title/Abstract] AND "therapy"[Title/Abstract]) OR ("resynchronisation"[Title/Abstract] AND "therapy"[Title/Abstract]) OR ("resynchronization"[Title/Abstract] AND "device*"[Title/Abstract]) OR ("resynchronisation"[Title/Abstract] AND "device*"[Title/Abstract]) OR

	"biventricular"[Title/Abstract] OR "CIED*"[Title/Abstract] OR ("biventricular"[Title/Abstract] AND "implantable"[Title/Abstract] AND "cardioverter"[Title/Abstract] AND "defibrillator*"[Title/Abstract]) OR ("cardiac"[Title/Abstract] AND "implantable"[Title/Abstract] AND "electronic"[Title/Abstract] AND "device*"[Title/Abstract])
#2	("remote"[Title/Abstract] AND "monitor*"[Title/Abstract]) OR ("remote"[Title/Abstract] AND "manag*"[Title/Abstract]) OR ("remote"[Title/Abstract] AND "follow up"[Title/Abstract]) OR ("remote"[Title/Abstract] AND "transmission"[Title/Abstract]) OR ("wireless"[Title/Abstract] AND "monitor*"[Title/Abstract]) OR ("wireless"[Title/Abstract] AND "manag*"[Title/Abstract]) OR ("wireless"[Title/Abstract] AND "follow up"[Title/Abstract]) OR ("wireless"[Title/Abstract] AND "transmission"[Title/Abstract]) OR "homemonitor*"[Title/Abstract] OR "remotemanagement"[Title/Abstract] OR "home monitor*"[Title/Abstract] OR "telemonitor*"[Title/Abstract] OR "Telemetry"[MeSH Terms] OR "Telemetry"[Title/Abstract] OR "telemedicine"[MeSH Terms] OR "telemedicine"[Title/Abstract]
#3	("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "drug therapy"[MeSH Subheading] OR "randomly"[Title/Abstract] OR "trial"[Title/Abstract] OR "groups"[Title/Abstract]) NOT ("animals"[MeSH Terms] NOT

	"humans"[MeSH Terms])
#4	#1 AND #2 AND #3

Study records

Data management

Database citations will be exported using Mendeley Reference Manager

(https://www.mendeley.com/reference-management/reference-manager; Elsevier,

Amsterdam, Netherlands). The search results will be uploaded to Rayyan

(http://rayyan.qcri.org; Rayyan Systems, Cambridge, MA, USA), a free web and mobile

application that facilitates abstract and title screening and collaboration among

reviewers [15].

Study selection

Three reviewers will independently screen the titles and abstracts of each study

identified using the described search strategies. We will retrieve the full texts of studies

that appear to meet the eligibility criteria and those of which eligibility is questioned.

Disagreements between reviewers will be resolved through discussion.

Data collection process

Two reviewers will independently extract data in duplicate from each eligible study. To

ensure consistency between reviewers, the first 5 titles will be screened via a data

collection form and discussion. Discrepancies will be resolved via discussion (including

a third reviewer if necessary). If data are missing or presented ambiguously, we will

contact the study authors for clarification.

Data items

A data collection sheet will be created. The following data will be extracted:

1.   patient characteristics (age, sex, device type, New York Heart Association

functional class, underlying heart disease, and left ventricular ejection fraction)

2.   intervention and control details (RM interrogation schedule, in-person outpatient

visit timing, and alert transmission criteria)

3.   outcome data (including mortality, hospitalisation, and dropout rate)

4.   study details (title, author information, year of publication, trial design, trial size,

eligibility criteria, exclusion criteria, duration of follow-up, type and source of

financial support, study settings, and publication status)

Values, for example, means, will be approximated from figures if necessary.

Outcomes and prioritisation

Primary outcome

Hospitalisation including cardiovascular, heart failure, and device-related

hospitalisation.

Secondary outcomes

All-cause mortality, cardiovascular mortality, unscheduled outpatient visits, and

unscheduled hospitalisation.

If outcomes are reported as a composite endpoint, we will extract individual outcomes

of interest from study results if extractable. If not extractable, we will contact the study

authors for clarification.

Risk of bias in individual studies

One reviewer will assess the risk of bias, and a second reviewer will verify the

assessment to confirm agreement. Any disagreements will be resolved through

discussion. The revised Cochrane risk-of-bias tool for RCTs (RoB 2.0; cochrane.org)

[16] will be used. The tool assesses bias across 5 domains, and the overall risk of bias is

determined based on the results of these domains:

1. Bias arising from the randomisation process

2. Bias due to deviations from intended interventions

3. Bias due to missing outcome data

4. Bias in the measurement of outcomes

5. Bias for selection of the reported result

Each domain's risk of bias and overall risk of bias will be described as "low," "some

concern," or "high."

Data synthesis and analysis

Summary measures (measures of treatment effect)

Dichotomous outcomes such as hospitalisation and mortality will be analysed using risk

ratio (RR) with 95% confidence intervals (CI). Continuous outcomes will be analysed

using mean difference (MD) or standardised mean difference (SMD) if different

measurement scales are used with 95% CI. If data is missing, we will contact the

authors of the study to obtain the relevant missing data.

Pairwise meta-analysis

If multiple studies with conventional in-person outpatient visits as a comparator are

identified, we will conduct pairwise meta-analyses to assess the effectiveness of RM

intervention for each outcome. We will use the Hartung-Knapp-Sidik-Jonkman

[17,18,19] meta-analysis with random effects method to combine the results and present

summary measures alongside the estimated effects of each study using forest plots.

Heterogeneity will be quantified using I^2 statistics.

Network meta-analysis

Review of network geometry

We will construct a network diagram and evaluate the network geometry [13].

Evaluating the geometry of the network allows for an assessment of the feasibility of

NMA, such as determining whether the network of interventions is connected.

Additionally, this assessment includes the identification of closed loops of treatments

within the network, facilitating the evaluation of inconsistency that is the disagreement

between effects estimated from direct and indirect sources.

Transitivity and inconsistency in NMA

We will statistically evaluate both local and global inconsistency. The local assessment

will be performed using the side-splitting method [20] while the global assessment will

be conducted via the design-by-treatment interaction model [21].

We will perform a random-effects NMA assuming a common between-studies

variance across the whole network. Summary effect measures such as RR will be

estimated along with 95% CI. The results of the estimation will be presented using the

league table and the Surface Under the Cumulative Ranking curve (SUCRA) [22], or

the P-score, a frequentist version of SUCRA[23]. We will use the R package "nma"

(cran.r-project.org/web/packages/NMA/index.html) to estimate SUCRA [24], and the R

package "netmeta" (cran.r-project.org/web/packages/netmeta/index.html) to calculate

P-score [25].

Component network meta-analysis

Additivity assumption in CNMA

CNMA allows the estimation of component effects of multicomponent interventions. In

this context, an additivity assumption is used, which means that the effect of each

intervention can be expressed as the sum of the effects of its individual components. We

will use the method based on a comparison of treatment estimates from the standard

NMA and the additive CNMA model to assess the additivity assumption [11,26].

If additivity holds, we will use an additive effects-based CNMA model for estimating

the relative effects of components. The results of the estimation will be presented using

the league table and the P-score [23]. We will use the R package "netmeta"

(cran.r-project.org/web/packages/netmeta/index.html) [25].

Narrative synthesis

If quantitative synthesis is not feasible due to significant between-studies heterogeneity

or an insufficient number of studies, we will conduct systematic narrative synthesis.

This approach will use information from the text and tables to summarise and describe

the characteristics and findings of the included studies.

Additional analyses

Sensitivity analysis

To assess the robustness of our findings based on the primary analysis, we plan to

perform a sensitivity analysis after excluding studies with a high risk of bias.

Subgroup analysis

We will conduct a subgroup analysis classified by device type (ICD or CRT-D) to

examine the consistency of results and validate the robustness of our findings.

Statistical analyses will be performed using the latest versions of R software (R

Foundation for Statistical Computing, Vienna, Austria) [27] and RStudio (RStudio,

Boston, MA, USA) [28] at the time of analysis.

Risk of bias across studies

If a study protocol is available, we will compare outcomes reported in the protocol or

trial registry with those in the published studies to assess the potential risk of reporting

bias. Small study effects will be assessed using Egger's regression to detect funnel plot

asymmetry [29] using a significance threshold of $p<0.1$.

Confidence in cumulative estimate

We will use the Grading of Recommendations Assessment, Development, and

Evaluation (GRADE) approach to assess the certainty of evidence for each outcome in

pairwise meta-analyses [30]. The quality of evidence will be assessed across the

following domains: limitations in study design, risk of bias, inconsistency, indirectness,

imprecision of the results, and publication bias. The quality of evidence will be

categorised as high, moderate, low, or very low. The Confidence in Network

Meta-Analysis (CINeMA) approach will be used to evaluate confidence in the NMA

estimates [31-33].

IMPLICATION AND LIMITATION

In the proposed study, we will aim to estimate the effect size of each RM component on

patient outcomes. The current follow-up practices for CIEDs, including ICDs and

CRT-Ds, recommend RM [3,4] based on known benefits including reductions in

all-cause mortality and emergency clinic visits [6, 7]. However, managing the increasing

population of patients with CIEDs using conventional remote management (periodic

remote interrogation + alert transmission + in-person outpatient visits) is a major

clinical and administrative burden [34]. Therefore, by identifying the most effective

components of RM, follow-up can be optimised without compromising patient

outcomes. However, CNMA assumes both consistency and additivity. If these

assumptions are not met, the accuracy of the estimated results will potentially be

compromised, therefore necessitating careful interpretation.

ETHICS AND DISSEMINATION

Ethics approval is not required as this study will use existing published data. The results

will be submitted for publication in a peer-reviewed journal.

Any significant changes to this protocol will be noted with a description of the change,

the corresponding rationale, and the date of the amendment when the results are

reported.

Acknowledgments

We would like to thank Editage (www.editage.com) for English-language editing.

Data availability statement

Data sharing not applicable as no datasets were generated and/or analysed for this study.

Funding statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests statement

None declared.

Authors' contributions

TM drafted the protocol. MO, TM, and YS led the development of the review protocol and drafted the manuscript. TM and MO contributed to the development of the selection criteria, risk of bias assessment strategy and data extraction criteria. TM and MO developed the search strategy. HN provided expertise on statistical analysis. MO, NS, YS, and TM read all drafts of the manuscript, provided feedback and approved the final manuscript.

REFERENCES

1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e73–189. doi: 10.1016/j.hrthm.2017.10.036

2. Authors/Task Force Members: McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. doi: 10.1002/ejhf.2333

3. Slotwiner D, Varma N, Akar JG, et al. HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm 2015;12:e69–100. doi: 10.1016/j.hrthm.2015.05.008

4. Ferrick AM, Raj SR, Deneke T, et al. 2023 HRS/EHRA/APHRS/LAHRS expert consensus statement on practical management of the remote device clinic. Heart Rhythm 2023;20:e92–144. doi: 10.1016/j.hrthm.2023.03.1525

5. Varma N, Epstein AE, Irimpen A, et al.; TRUST Investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010;122:325–32. doi: 10.1161/CIRCULATIONAHA.110.937409

6.   Hindricks G, Taborsky M, Glikson M, et al.; IN-TIME study group. Implant-based

multiparameter telemonitoring of patients with heart failure (IN-TIME): a

randomised controlled trial. Lancet 2014;384:583–90. doi:

10.1016/S0140-6736(14)61176-4

7.   Landolina M, Perego GB, Lunati M, et al. Remote monitoring reduces healthcare

use and improves quality of care in heart failure patients with implantable

defibrillators: the evolution of management strategies of heart failure patients with

implantable defibrillators (EVOLVO) study. Circulation 2012;125:2985–92. doi:

10.1161/CIRCULATIONAHA.111.088971

8.   Boriani G, Da Costa A, Quesada A, et al.; MORE-CARE Study Investigators.

Effects of remote monitoring on clinical outcomes and use of healthcare resources

in heart failure patients with biventricular defibrillators: results of the

MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail

2017;19:416–25. doi: 10.1002/ejhf.626

9.   Braunschweig F, Anker SD, Proff J,et al. Remote monitoring of implantable

cardioverter-defibrillators and resynchronization devices to improve patient

outcomes: dead end or way ahead? Europace 2019;21:846–55. doi:

10.1093/europace/euz011

10. Seiler A, Biundo E, Di Bacco M, et al. Clinic Time Required for Remote and

In-Person Management of Patients With Cardiac Devices: Time and Motion

Workflow Evaluation. JMIR Cardio 2021;5:e27720. doi: 10.2196/27720

11. Rücker G, Petropoulou M, Schwarzer G. Network meta-analysis of

multicomponent interventions. Biom J 2020;62:808–21. doi:

10.1002/bimj.201800167

12. Shamseer L, Moher D, Clarke M, et al.; PRISMA-P Group. Preferred reporting

items for systematic review and meta-analysis protocols (PRISMA-P) 2015:

elaboration and explanation. BMJ 2015;350:g7647. doi: 10.1136/bmj.g7647.

Erratum in: BMJ 2016;354:i4086.

13. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for

reporting of systematic reviews incorporating network meta-analyses of health care

interventions: checklist and explanations. Ann Intern Med 2015;162:777–84. doi:

10.7326/M14-2385

14. Chaimani A, Caldwell DM, Li T, et al. Chapter 11: Undertaking network

meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,

Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions

version 6.4 (updated August 2023). London: Cochrane, 2023.

www.training.cochrane.org/handbook

15. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for

systematic reviews. Syst Rev 2016;5:210. doi: 10.1186/s13643-016-0384-4

16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of

bias in randomised trials. BMJ 2019;366:l4898. doi: 10.1136/bmj.l4898

17. Hartung J, Knapp G. On tests of the overall treatment effect in meta-analysis with

normally distributed responses. Stat Med. 2001 Jun 30;20(12):1771-82. doi:

10.1002/sim.791.

18. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical

trials with binary outcome. Stat Med 2001; 20: 3875-3889.

19. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for

random effects meta-analysis is straightforward and considerably outperforms the

standard DerSimonian-Laird method. BMC Med Res Methodol. 2014 Feb 18;14:25.

doi: 10.1186/1471-2288-14-25.

20. Noma H, Tanaka S, Matsui S, et al. Quantifying indirect evidence in network

meta-analysis. Stat Med 2017;36:917–27. doi: 10.1002/sim.7187

21. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network

meta-analysis: model estimation using multivariate meta-regression. Res Synth

Methods 2012;3:111–25. doi: 10.1002/jrsm.1045

22. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for

presenting results from multiple-treatment meta-analysis: an overview and tutorial.

J Clin Epidemiol 2011;64:163–71. doi: 10.1016/j.jclinepi.2010.03.016

23. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis

works without resampling methods. BMC Med Res Methodol 2015;15:58. doi:

10.1186/s12874-015-0060-8

24. Noma H, Maruo K, Tanaka S, et al. NMA: Network Meta-Analysis Based on

Multivariate Meta-Analysis Models. R Package Version 1.4-1. 2023.

https://cran.r-project.org/web/packages/NMA/.

25. Rücker G, Krahn U, König J, et al. netmeta: Network Meta-Analysis using

Frequentist Methods. R Package Version 2.8-2. 2023.

https://cran.r-project.org/web/packages/netmeta/index.html

26. Rücker G, Schmitz S, Schwarzer G. Component network meta-analysis compared

to a matching method in a disconnected network: A case study. Biom J

2021;63:447–61. doi: 10.1002/bimj.201900339

27. R Core Team. R: A language and environment for statistical computing. R

Foundation for Statistical Computing, Vienna, Austria. 2021.

https://www.R-project.org/

28. RStudio Team. RStudio: Integrated Development for R. RStudio, PBC, Boston,

MA, USA. 2020. http://www.rstudio.com/.

29. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a

simple, graphical test. BMJ 1997;315:629–34. doi: 10.1136/bmj.315.7109.629

30. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an

emerging consensus on rating quality of evidence and strength of recommendations.

BMJ 2008;336:924–6. doi: 10.1136/bmj.39489.470347.AD

31. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence

from a network meta-analysis. PLoS One 2014;9:e99682. doi:

10.1371/journal.pone.0099682

32. Papakonstantinou T, Nikolakopoulou A, Higgins JPT, et al. CINeMA: Software for

semiautomated assessment of the confidence in the results of network

meta-analysis. Campbell Syst Rev 2020;16:e1080. doi: 10.1002/cl2.1080

33. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach

for assessing confidence in the results of a network meta-analysis. PLoS Med

2020;17:e1003082. doi: 10.1371/journal.pmed.1003082

34. Seiler A, Biundo E, Di Bacco M, et al. Clinic Time Required for Remote and

In-Person Management of Patients With Cardiac Devices: Time and Motion

Workflow Evaluation. JMIR Cardio 2021;5:e27720. doi: 10.2196/27720